Contents

Preface

1 Basics of Personalized Medicine
   Definition of Personalized Medicine
   History of Medical Concepts Relevant to Personalized Medicine
   Molecular Biological Basis of Personalized Medicine
      The Human Genome
      Chromosomes
      Genes
      The Genetic Code
      Gene Expression
      DNA Sequences and Structure
      Single Nucleotide Polymorphisms
      Genotype and Haplotypes
   Genetic Variations in the Human Genome
      Insertions and Deletions in the Human Genome
      Large Scale Variation in Human Genome
      Variation in Copy Number in the Human Genome
      Structural Variants in the Human Genome
      Mapping and Sequencing of Structural Variants from Human Genomes
      1,000 Genomes Project
      Human Variome Project
   Basics Technologies for Developing Personalized Medicine
      Definitions of Technologies Relevant to Personalized Medicine
      Problems with the ICH Definitions of Pharmacogenomics and Pharmacogenetics
      Relationship of Various Technologies to Personalized Medicine
      Conventional Medicine vs. Personalized Medicine
   Genetic Basis of Personalized Medicine
      Genetic Medicine
      Human Disease and Genes
Genetic and Environmental Interactions in Etiology of Human Diseases ................................................................. 19
Mass Analysis of DNA from Whole Populations ........................................................................................................... 19
Role of Genetics in Development of Personalized Medicines .......................................................... 20
Genetic Databases ...................................................................................................................................................... 20
Genetic Epidemiology ............................................................................................................................................... 21
Limitations of Medical Genetics and Future Prospects ......................................................................................... 22
Genetics vs. Epigenetics ........................................................................................................................................ 22
Role of Systems Biology in Personalized Medicine .............................................................................................. 22
Systems Pharmacology ........................................................................................................................................... 24
Systems Medicine .................................................................................................................................................. 24
A Personalized Approach to Environmental Factors in Disease ................................................................................. 25
Reclassification of Diseases .................................................................................................................................... 26
Summary .................................................................................................................................................................. 27

2 Molecular Diagnostics as Basis of Personalized Medicine .......................................................... 29
Introduction ......................................................................................................................................................... 29
Molecular Diagnostic Technologies ......................................................................................................................... 29
DNA Sequencing .................................................................................................................................................... 30
Biochips and Microarrays ...................................................................................................................................... 30
DNA Biochip Technology for Developing Personalized Medicine ......................................................................... 30
Role of Protein Biochips in Personalized Medicine ............................................................................................. 34
Cytogenetics ......................................................................................................................................................... 35
Molecular Cytogenetics as Basis for Personalized Medicine ............................................................................... 35
Cytomics as a Basis for Personalized Medicine .................................................................................................... 36
SNP Genotyping .................................................................................................................................................... 37
Technologies for SNP Analysis ................................................................................................................................. 37
Applications of SNPs Relevant to Personalized Medicine .................................................................................. 37
Concluding Remarks on SNP Genotyping ............................................................................................................. 39
Haplotyping ............................................................................................................................................................ 40
HapMap Project ........................................................................................................................................................ 41
Predicting Drug Response with HapMap .................................................................................................................. 42
Nanodiagnostics for Personalized Medicine ........................................................................................................ 42
Cantilevers for Personalized Medical Diagnostics ............................................................................................... 43
Nanopore-Based Technology for Single Molecule Identification ................................................................................. 44
Application of Proteomics in Molecular Diagnosis ............................................................................................. 44
Comparison of Proteomic and Genomic Approaches in Personalized Medicine .......................................................... 44
Gene Expression Profiling ........................................................................................................................................ 45
DNA Microarrays for Gene Expression Studies ......................................................................................................... 46
Analysis of Single-Cell Gene Expression .................................................................................................................. 47
Gene Expression Profiling Based on Alternative RNA Splicing .......................................................................... 47
Molecular Imaging and Personalized Medicine ..................................................................................................... 48
Monitoring In Vivo Gene Expression by Molecular Imaging .................................................................................. 49
Glycomics-Based Diagnostics .................................................................................................................................. 49
Combination of Diagnostics and Therapeutics ........................................... 50
Point-of-Care Diagnosis .............................................................................. 50
  Point-of-Care Diagnosis of Infections .................................................... 52
Advantages vs. Disadvantages of Point-of-Care Diagnosis .................... 52
Future Prospects of Point-of-Care Diagnosis ......................................... 53
Genetic Testing for Disease Predisposition ............................................ 53
Personal Genetic Service ........................................................................ 54
Role of Diagnostics in Integrated Healthcare ........................................... 54
  Concept of Integrated Healthcare ........................................................... 54
Components of Integrated Healthcare..................................................... 55
  Screening ............................................................................................. 55
  Disease Prediction ............................................................................... 55
  Early Diagnosis ................................................................................... 55
  Prevention ........................................................................................... 56
  Therapy Based on Molecular Diagnosis ............................................. 56
  Monitoring of Therapy ........................................................................ 56
Advantages and Limitations of Integrated Healthcare ............................ 56
Future of Molecular Diagnostics in Personalized Medicine ....................... 57
Summary ..................................................................................................... 57

3 Role of Biomarkers in Personalized Medicine ....................................... 59
  Introduction ......................................................................................... 59
  Technologies for Discovery of Biomarkers ........................................... 60
    Systems Biology Approach to Biomarker Identification ........................ 60
    Epigenomic Technologies ................................................................... 60
      Discovery of Methylation Biomarkers ............................................. 62
    Proteomic Strategies for Biomarker Identification ............................. 62
      Proteomic Technologies for Detection of Biomarkers ........................ 63
        in Body Fluids ............................................................................... 63
  Biomarkers for Diagnostics ................................................................. 63
  Biomarkers for Drug Development ....................................................... 64
    Use of Biomarkers for Developing MAb Therapy in Oncology .......... 64
  Biobanking, Biomarkers and Personalized Medicine ............................. 65
    Expression Signatures as Diagnostic/Prognostic Tools ...................... 66
  Biomarkers for Monitoring Response to Therapy .................................. 66
  Drug Rescue by Biomarker-Based Personalized Medicine .................... 67
Future Role of Biomarkers in Personalized Medicine ................................ 68
Summary ..................................................................................................... 68

4 Pharmacogenetics .................................................................................. 69
  Basics of Pharmacogenetics ................................................................. 69
  Role of Molecular Diagnostics in Pharmacogenetics .............................. 70
  Role of Pharmacogenetics in Pharmaceutical Industry .......................... 71
    Study of the Drug Metabolism and Pharmacological Effects .............. 71
    Causes of Variations in Drug Metabolism ......................................... 72
| Enzymes Relevant to Drug Metabolism | 72 |
| Pharmacogenetics of Phase I Metabolism | 73 |
| Cyp450 | 73 |
| P450 CYP 2D6 Inhibition by Selective Serotonin Reuptake Inhibitors (SSRIs) | 75 |
| Cytochrome P450 Polymorphisms and Response to Clopidogrel | 76 |
| Lansoprazole and Cytochrome P450 | 76 |
| Glucose-6-Phosphate Dehydrogenase | 77 |
| Pharmacogenetics of Phase II Metabolism | 78 |
| N-Acetyltransferase | 78 |
| Uridine Diphosphate-Glucuronosyltransferase | 79 |
| Measurement of CYP Isoforms | 79 |
| Polymorphism of Drug Transporters | 80 |
| Genetic Variation in Drug Targets | 81 |
| Polymorphisms of Kinase Genes | 82 |
| Effect of Genetic Polymorphisms on Response of Disease to Drugs | 82 |
| Ethnic Differences in Drug Metabolism | 83 |
| Gender Differences in Pharmacogenetics | 83 |
| Role of Pharmacogenetics in Drug Safety | 84 |
| Adverse Drug Reactions | 84 |
| ADRs in Children | 84 |
| Genetically Determined ADRs | 85 |
| ADRs of Chemotherapy | 86 |
| Malignant Hyperthermia | 87 |
| Pharmacogenetics of Clozapine-Induced Agranulocytosis | 87 |
| Role of Pharmacogenetics in Warfarin Therapy | 88 |
| Role of Pharmacogenetics in Carbamazepine Therapy | 89 |
| Role of Pharmacogenetics in Statin Therapy | 89 |
| FDA Consortium for Genetic Biomarkers of Serious Adverse Events | 90 |
| Therapeutic Drug Monitoring, Phenotyping, and Genotyping | 91 |
| Therapeutic Drug Monitoring | 91 |
| Phenotyping | 91 |
| Genotyping | 93 |
| Genotyping vs. Phenotyping | 93 |
| Phenomics | 94 |
| Limitations of Genotype-Phenotype Association Studies | 95 |
| Molecular Toxicology in Relation to Personalized Medicines | 95 |
| Toxicogenomics | 95 |
| Gene Expression Studies | 96 |
| Genomics and the Prediction of Xenobiotic Toxicity | 97 |
| Pharmacogenetics in Clinical Trials | 97 |
| Clinical Implications of Pharmacogenetics | 98 |
| Application of CYP450 Genotyping in Clinical Practice | 98 |
| Genotype-Based Drug Dose Adjustment | 98 |
### Contents

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Examples of use of Pharmacogenetics in Clinical Pharmacology</td>
<td>99</td>
</tr>
<tr>
<td>Linking Pharmacogenetics with Pharmacovigilance</td>
<td>100</td>
</tr>
<tr>
<td>Genetic Susceptibility to ADRs</td>
<td>100</td>
</tr>
<tr>
<td>Linking Genetic Testing to Postmarketing ADR Surveillance</td>
<td>100</td>
</tr>
<tr>
<td>Recommendations for the Clinical Use of Pharmacogenetics</td>
<td>101</td>
</tr>
<tr>
<td>Limitations of Pharmacogenetics</td>
<td>101</td>
</tr>
<tr>
<td>Future Role of Pharmacogenetics in Personalized Medicine</td>
<td>102</td>
</tr>
<tr>
<td>Summary</td>
<td>102</td>
</tr>
</tbody>
</table>

5 Pharmacogenomics ................................................................................... 105
| Introduction                                                          | 105   |
| Basics of Pharmacogenomics                                           | 105   |
| Pharmacogenomics and Drug Discovery                                  | 107   |
| Preclinical Prediction of Drug Efficacy                              | 108   |
| Pharmacogenomics and Clinical Trials                                 | 109   |
| Impact of Genetic Profiling on Clinical Studies                      | 109   |
| Limitations of the Pharmacogenomic-Based Clinical Trials             | 111   |
| Pharmacogenomic Aspects of Major Therapeutic Areas                   | 112   |
| Oncogenomics                                                         | 112   |
| Oncogenes                                                            | 112   |
| Tumor Suppressor Genes                                               | 113   |
| Cardiogenomics                                                       | 113   |
| Neurogenomics                                                        | 117   |
| Pharmacogenomics of AD                                               | 117   |
| Pharmacogenomics of Depression                                       | 118   |
| Pharmacogenomics of Schizophrenia                                    | 118   |
| Summary                                                              | 119   |

6 Role of Pharmacoproteomics ................................................................... 121
| Basics of Proteomics                                                 | 121   |
| Proteomic Approaches to the Study of Pathophysiology of Diseases     | 122   |
| Single Cell Proteomics for Personalized Medicine                     | 122   |
| Diseases Due to Misfolding of Proteins                               | 123   |
| Therapies for Protein Misfolding                                     | 123   |
| Significance of Mitochondrial Proteome in Human Disease              | 124   |
| Proteomic Technologies for Drug Discovery and Development            | 125   |
| Role of Reverse-Phase Protein Microarray in Drug Discovery           | 125   |
| Role of Proteomics in Clinical Drug Safety                           | 125   |
| Toxicoproteomics                                                     | 126   |
| Application of Pharmacoproteomics in Personalized Medicine           | 128   |
| Summary                                                              | 128   |

7 Role of Metabolomics in Personalized Medicine .................................... 129
| Metabolomics and Metabonomics                                        | 129   |
| Metabolomics Bridges the Gap Between Genotype and Phenotype          | 130   |
Metabolomics, Biomarkers and Personalized Medicine ........................................... 131
Metabolomic Technologies .................................................................................... 131
Urinary Profiling by Capillary Electrophoresis ..................................................... 132
Lipid Profiling ....................................................................................................... 133
Role of Metabolomics in Biomarker Identification and Pattern Recognition .......... 133
Validation of Biomarkers in Large-Scale Human Metabolomics Studies ............... 134
Pharmacometabonomics ....................................................................................... 134
Metabonomic Technologies for Toxicology Studies .......................................... 135
Metabonomics/Metabolomics and Personalized Nutrition .................................... 136
Summary .............................................................................................................. 136

8 Personalized Biological Therapies .................................................................... 137
Introduction .......................................................................................................... 137
Recombinant Human Proteins ............................................................................. 137
Therapeutic Monoclonal Antibodies ..................................................................... 138
Cell Therapy .......................................................................................................... 138
Autologous Tissue and Cell Transplants ............................................................... 139
Stem Cells .............................................................................................................. 139
Role of Stem Cells Derived from Unfertilized Embryos ........................................ 139
Cloning and Personalized Cell Therapy ............................................................... 140
Use of Stem Cells for Drug Testing ...................................................................... 140
Gene Therapy ......................................................................................................... 140
Personalized Vaccines .......................................................................................... 141
Personalized Vaccines for Viral Diseases ............................................................. 141
Personalized Cancer Vaccines ............................................................................ 142
Patient-Specific Cancer Vaccines ......................................................................... 142
Antigen-Specific Vaccines .................................................................................... 143
Autologous Cell Vaccines .................................................................................... 143
Personalized Melanoma Vaccines ....................................................................... 145
Antisense Therapy ................................................................................................ 145
RNA Interference .................................................................................................. 146
MicroRNAs ............................................................................................................. 146
Summary ................................................................................................................. 147

9 Development of Personalized Medicine .......................................................... 149
Introduction .......................................................................................................... 149
Non-genomic Factors in the Development of Personalized Medicine ................. 150
Personalized Medicine Based on Circadian Rhythms .......................................... 150
Intestinal Microflora .............................................................................................. 151
Gut Microbiome Compared to Human Genome ................................................... 151
Metabolic Interactions of the Host and the Intestinal Microflora ........................... 152
Role of Drug Delivery in Personalized Medicine ................................................. 152
Role of Molecular Imaging in Personalized Medicine ......................................... 153
Personalized Approach to Clinical Trials ............................................. 153
Use of Bayesian Approach in Clinical Trials................................. 153
Individualizing Risks and Benefits in Clinical Trials .................. 154
Clinical Trials of Therapeutics and Companion Diagnostics .......... 155
Role of Genetic Banking Systems and Databases ......................... 155
Role of Biobanks in the Development of Personalized Medicine ...... 155
UK Biobank ..................................................................................... 156
Biobanking and Development of Personalized Medicine in the EU ... 156
CARTaGENE for Biobanks in Canada .............................................. 157
Personalized Medicine Based on PhysioGenomics™ Technology .... 158
Role of Bioinformatics in Development of Personalized Medicine ... 159
Health Information Management ..................................................... 160
Electronic Health Records ............................................................. 160
Linking Patient Medical Records and Genetic Information .......... 161
Management of Personal Genomic Data ............................................ 161
Personalized Prognosis of Disease .................................................. 162
Integration of Technologies for Development of Personalized Medicine .................................................. 163
Summary .......................................................................................... 163

10 Personalized Therapy for Cancer ................................................. 165
Introduction ...................................................................................... 165
Challenges of Cancer Classification .............................................. 165
Relationships of Technologies for Personalized Management of Cancer .................................................................................. 166
Impact of Molecular Diagnostics on the Management of Cancer .... 167
Analysis of RNA Splicing Events in Cancer .................................. 167
Analysis of Chromosomal Alterations in Cancer Cells ................. 168
Cancer Classification Using Microarrays ....................................... 168
Detection of Loss of Heterozygosity (LOH) ................................. 169
Diagnosis of Cancer of an Unknown Primary ............................... 170
Diagnostics for Detection of Minimal Residual Disease (MRD) ..... 170
Fluorescent In Situ Hybridization ................................................ 171
Gene Expression Profiling ............................................................... 171
Gene Expression Profiles Predict Chromosomal Instability in Tumors .......................................................... 172
Isolation and Characterization of Circulating Tumor Cells (CTCs) .... 173
Modulation of CYP450 Activity for Cancer Therapy .................. 173
Personalized Therapies Based on Oncogenic Pathway Signatures .... 174
Role of Molecular Imaging in Personalized Therapy of Cancer ...... 175
Molecular Imaging for Personalized Drug Development in Oncology .............................................................................. 175
Molecular Imaging as Guide to Cancer Treatment ....................... 176
Functional Diffusion MRI ............................................................... 177
Role of FDG-PET/CT in Personalizing Cancer Treatment 178
Tumor Imaging and Elimination by Targeted Gallium Corrole 179
Unraveling the Genetic Code of Cancer 179
Cancer Prognosis 180
Detection of Mutations for Risk Assessment and Prevention 181
Impact of Biomarkers on Management of Cancer 181
Predictive Biomarkers for Cancer 181
HER-2/neu Oncogene as a Biomarker for Cancer 182
L-asparaginase (L-ASP) Treatment of Cancer Guided by a Biomarker 182
Determination of Response to Therapy 183
Phenotype-Based Cell Culture Assays 183
Ex Vivo Testing of Tumor Biopsy for Chemotherapy Sensitivity 183
Genomic Approaches to Predict Response to Anticancer Agents 184
Gene Expression Patterns to Predict Response of Cancer to Therapy 184
Genomic Analysis of Tumor Biopsies 184
Mutation Detection at Molecular Level 185
Role of Genetic Variations in Susceptibility to Anticancer Drugs 185
Proteomic Analysis of Tumor Biopsies to Predict Response to Treatment 185
Real-time Apoptosis Monitoring 186
Serum Nucleosomes as Indicators of Sensitivity to Chemotherapy 186
Targeted Microbubbles to Tumors for Monitoring Anticancer Therapy 187
Tissue Systems Biology Approach to Personalized Management of Cancer 188
Targeted Cancer Therapies 188
Targeting Glycoproteins on Cell Surface 188
Targeting Pathways in Cancer 189
Functional Antibody-Based Personalized Therapies 189
Personalized Radiation Therapy 190
Molecular Diagnostics Combined with Cancer Therapeutics 191
Aptamers for Combined Diagnosis and Therapeutics of Cancer 192
Role of Nanobiotechnology in Personalized Management of Cancer 192
Design of Future Cancer Therapies 193
Screening for Personalized Anticancer Drugs 194
Role of Epigenetics in Development of Personalized Cancer Therapies 194
Personalized Therapy of Cancer Based on Cancer Stem Cells 195
Role of Oncoproteomics in Personalized Therapy of Cancer 195
Cancer Tissue Proteomics 196
Pharmacogenomic-Based Chemotherapy 197
Whole Genome Technology to Predict Drug Resistance 197
Anticancer Drug Selection Based on Molecular Characteristics of Tumor ......................................................... 197
Testing Microsatellite-Instability for Response to Chemotherapy ...... 198
Pharmacogenetics of Cancer Chemotherapy ................................. 199
CYP1A2 .................................................................................. 199
Thiopurine Methyltransferase ...................................................... 200
Dihydropyrimidine Dehydrogenase .............................................. 201
UGT1A1 Test as Guide to Irinotecan Therapy ............................... 201
Role of Computational Models in Personalized Anticancer Therapy .... 202
A Computational Model of Kinetically Tailored Treatment .......... 202
Mathematical Modeling of Tumor Microenvironments .................. 202
Molecular Profiling of Cancer .................................................... 203
Drug Resistance in Cancer ....................................................... 204
Detection of Drug Resistance in Cancer by Metabolic Profiling ....... 205
Determination of Chemotherapy Response by Topoisomerase Levels ......................................................... 205
A Systems Biology Approach to Drug Resistance in CRC ........... 206
Management of Drug Resistance in Leukemia ............................. 206
Overexpression of Multidrug Resistance Gene ............................. 207
P53 Mutations ......................................................................... 207
A Chemogenomic Approach to Drug Resistance ....................... 208
Examples of Personalized Management of Cancer ....................... 208
Personalized Management of Breast Cancer ............................... 208
Genetic Testing in Breast Cancer as a Guide to Treatment .......... 209
Pharmacogenetics of Breast Cancer .......................................... 210
Molecular Diagnostics in Breast Cancer ..................................... 210
Racial Factors in the Management of Breast Cancer .................... 212
Proteomics-Based Personalized Management of Breast Cancer .... 212
Tests for Prognosis of Breast Cancer ......................................... 213
Developing Personalized Drugs for Breast Cancer ...................... 215
Developing Personalized Drugs for Triple-Negative Breast Cancer ................................................................. 216
Predicting Response to Chemotherapy in Breast Cancer ............. 216
Prediction of Resistance to Therapy in Breast Cancer ............... 219
Prediction of Adverse Reaction to RT in Breast Cancer .............. 220
Prediction of Recurrence in Breast Cancer for Personalizing Therapy ........................................................... 220
TAILORx (Trial Assigning Individualized Options for Treatment) .......................................................... 222
Gene Expression Plus Conventional Predictors of Breast Cancer .................................................................... 223
Future Development of Gene Expression Microarrays for Breast Cancer ...................................................... 224
Personalized Management of Ovarian Cancer .............................. 224
Personalized Management of Hematological Malignancies ......... 227
Personalized Management of Acute Leukemias............................... 227
Personalized Management of Chronic Lymphocytic Leukemia...... 229
Personalized Management of Multiple Myeloma (MM)................. 229
Personalized Management B Cell Lymphomas ............................... 231
Personalized Vaccine for Follicular Lymphoma............................ 231
Personalized Management of Myelodysplasia.............................. 232
Personalized Management of Malignant Melanoma......................... 232
Personalized Management of Gastrointestinal Cancer ....................... 232
Personalized Management of Esophageal Cancer............................ 232
Personalized Management of CRC.............................................. 233
Personalized Management of Lung Cancer.................................... 236
Determination of Outcome of EGFR Tyrosine Kinase
Inhibitor Treatment ....................................................................... 236
Testing for Response to Chemotherapy in Lung Cancer ................. 239
Testing for Prognosis of NSCLC ............................................... 239
Testing for Recurrence of Lung Cancer ....................................... 240
Role of a New Classification System in the Management
of Lung Cancer ........................................................................... 240
Personalized Management of Prostate Cancer ................................. 241
Benefit of Lifestyle Changes Shown by Gene Expression Studies ...... 241
Personalized Management of Brain Cancer.................................... 242
Genetics and Genomics of Brain Cancer ...................................... 242
Molecular Diagnostics for Personalized Management
of Brain Cancer ........................................................................... 244
Personalized Chemotherapy of Brain Tumors ................................. 246
Biosimulation Approach to Personalizing Treatment
of Brain Cancer ........................................................................... 247
Personalized Therapy of Oligodendroglial Tumors.......................... 248
Personalized Therapy of Neuroblastomas ....................................... 249
Personalized Management of Germ Cell Brain Tumors ................. 250
Future of Cancer Therapy ............................................................ 250
Challenges for Developing Personalized Cancer Therapies ............... 250
The Cancer Genome Atlas ......................................................... 251
Role of the International Cancer Genome Consortium ..................... 251
Using Computer and Imaging Technologies
to Personalize Cancer Treatment ............................................... 253
Integrated Genome-Wide Analysis of Cancer for
Personalized Therapy ................................................................... 253
Summary ..................................................................................... 254

11 Personalized Management of Neurological Disorders............... 255
Introduction ................................................................................... 255
Personalized Drug Development for Neurological Disorders .......... 255
Personalized Drug Discovery ........................................................ 255
## Contents

Molecular Imaging and CNS Drug Development ............................................ 255
Personalized Management of AD ................................................................. 257
Personalized Management of PD ................................................................. 258
Discovery of Subgroup-Selective Drug Targets in PD ................................. 259
Personalized Management of Epilepsy .......................................................... 259
Choice of the Right AED ............................................................................. 260
Pharmacogenetics of Epilepsy ..................................................................... 260
Pharmacogenomics of Epilepsy ................................................................. 261
Drug Resistance in Epilepsy ........................................................................ 262
Future Prospects for Epilepsy ...................................................................... 263
Personalized Management of Migraine ......................................................... 264
Personalized Treatment of MS ................................................................. 264
MBP8298 ................................................................................................. 265
Pharmacogenomics of IFN-β Therapy in MS ............................................... 266
Future Prospects of Personalized Therapy of MS ........................................ 267
Personalized Management of Psychiatric Disorders ..................................... 267
Psychopharmacogenetics ........................................................................... 267
COMT Genotype and Response to Amphetamine .......................................... 268
Genotype and Response to Methylphenidate in Children with ADHD .......... 268
Personalized Antipsychotic Therapy ............................................................. 269
Personalized Antidepressant Therapy ........................................................... 272
Pretreatment EEG to Predict Adverse Effects to Antidepressants.... ........... 273
Individualization of SSRI Treatment ............................................................ 273
Vilazodone with a Test for Personalized Treatment of Depression ............. 275
Summary ....................................................................................................... 275

### 12 Personalized Therapy of Cardiovascular Diseases

Introduction ................................................................................................. 277
Role of Cardiovascular Diagnostics in Personalized Management .......... 277
Testing in Coronary Heart Disease ............................................................. 277
SNP Genotyping in Cardiovascular Disorders .............................................. 278
Cardiovascular Disorders with a Genetic Component ................................. 279
  Gene Variant as a Risk Factor for Sudden Cardiac Death ....................... 281
  SNP Chip for Study of Cardiovascular Diseases ....................................... 282
Pharmacogenomics of Cardiovascular Disorders ........................................ 282
Modifying the Genetic Risk for MI ............................................................. 283
Management of Heart Failure ................................................................. 283
  β-Blockers ............................................................................................... 283
  Bucindolol ............................................................................................... 284
  BiDil ....................................................................................................... 284
Management of Hypertension ...................................................................... 285
Pharmacogenomics of Diuretic Drugs ........................................................ 286
Pharmacogenomics of ACE Inhibitors ......................................................... 287
Management of Hypertension by Personalized Approach.............. 287
Pharmacogenetics of Lipid-Lowering Therapies........................ 288
Polymorphisms in Genes Involved in Cholesterol Metabolism...... 288
Role of eNOS Gene Polymorphisms ....................................... 289
The STRENGTH Study ......................................................... 290
Personalized Management of Women with Hyperlipidemia ......... 291
Thrombotic Disorders ............................................................ 291
Factor V Leiden Mutation ...................................................... 291
Anticoagulant Therapy .......................................................... 292
Nanotechnology-Based Personalized Therapy of Cardiovascular Diseases ......................................................... 293
Project euHeart for Personalized Management of Cardiovascular Diseases ........................................................................... 294
Concluding Remarks ............................................................. 294
Summary .................................................................................. 295

13 Personalized Management of Miscellaneous Disorders .......... 297
Management of Viral Infections ................................................. 297
Management of HIV ............................................................... 297
Genetics of Human Susceptibility to HIV Infection ................. 297
Pharmacogenomics of Antiretroviral Agents........................... 298
Role of Diagnostic Testing in HIV ......................................... 299
CD4 Counts as a Guide to Drug Therapy for AIDS ................. 299
Drug-Resistance in HIV .......................................................... 299
Measurement of Replication Capacity ..................................... 300
Prevention of Adverse Reactions to Antiviral Drugs ................ 300
Role of Genetic Variations in Susceptibility to HIV-1 ............... 301
Pharmacogenetics and HIV Drug Safety ................................. 302
Treatment of Hepatitis B ........................................................ 302
Treatment of Hepatitis C ......................................................... 302
Personalized Management of Tuberculosis (TB) ...................... 304
Personalized Management of Skin Disorders ......................... 305
Personalized Therapy of Rheumatoid Arthritis (RA) ................. 305
DIATSTAT™ Anti-Cyclic Citrullinated Peptides in RA ............... 307
Personalization of COX-2 Inhibitor Therapy ......................... 307
Personalization of Infliximab Therapy ..................................... 308
Personalized Therapy of Asthma ............................................. 308
Genetic Polymorphism and Response to $\beta_2$-Adrenergic Agonists .... 308
Genotyping in Asthma ......................................................... 309
Personalized Approaches in Immunology ............................ 310
Pharmacogenetics and Pharmacogenomics of Immunosuppressive Agents .................................................. 311
Personalized Immunosuppressant Therapy in Organ Transplants ...... 311
Personalized Management of Pain ............................................. 312
Pharmacogenetics/Pharmacogenomics of Pain ......................... 313
Mechanism-Specific Management of Pain ........................................... 314
Preoperative Testing to Tailor Postoperative Analgesic Requirements ........................................... 314
Personalized Analgesics........................................................................ 315
Management of Genetic Disorders ........................................................... 316
Personalized Treatment of Cystic Fibrosis ........................................... 316
Personalized Management of Gastrointestinal Disorders ......................... 317
Personalized Therapy of Inflammatory Bowel Disease ........................ 317
Personalized Management of Lactose Intolerance ............................... 318
Personalized Approach to Addiction ........................................................ 318
Genetic Polymorphism and Management of Alcoholism………………… 318
Personalized Therapy for Smoking Cessation ...................................... 319
Antidepressant Therapy for Smoking Cessation...................................... 319
Effectiveness of Nicotine Patches in Relation to Genotype……………… 319
Personalized Approach to Drug Addiction ........................................... 320
Personalized Approaches to Miscellaneous Problems .............................. 320
Hormone Replacement Therapy in Women .......................................... 320
Personalized Treatment of Malaria ....................................................... 321
Personalized Management of Renal Disease ........................................ 322
Personalization of Organ Transplantation ............................................. 322
Personalization of Kidney Transplantation .......................................... 323
Personalization of Cardiac Transplantation .......................................... 323
Prediction of Rejection to Tailor Anti-Rejection Medications .......... 324
Role of Immunological Biomarkers in Monitoring Grafted Patients........... 325
Improved Matching of Blood Transfusion........................................... 325
Personalized Care of Trauma Patients ................................................. 326
Personalized Anticoagulation ............................................................... 326
Personalized Hyperbaric Oxygen Therapy ........................................... 327
Summary ................................................................................................... 328

14 Personalized Preventive Medicine ................................................. 329
Introduction ............................................................................................... 329
Personalized Nutrition .............................................................................. 330
Nutrigenomics ....................................................................................... 330
Nutrigenomics and Functional Foods .................................................. 331
Nutrigenomics and Personalized Medicine .......................................... 332
Nutrition and Proteomics ...................................................................... 332
Personalized Diet Prescription .............................................................. 333
Summary ................................................................................................... 333

15 Organization of Personalized Medicine ............................................ 335
Players in the Development of Personalized Medicine ......................... 335
Personalized Medicine Coalition ......................................................... 335
Role of Pharmaceutical Industry ......................................................... 336
Production and Distribution of Personalized Medicines .......... 338
Role of Biotechnology Companies ........................................ 339
Role of life Sciences Industries ............................................ 339
Collaboration Between the Industry and the Academia .......... 340
Role of the Clinical Laboratories ......................................... 340
Role of the US Government .................................................. 341
Role of US Government Institutions in Development of
  Personalized Medicine ....................................................... 342
  NIH’s Roadmap Initiative for Medical Research .................. 342
  NIH and Personalized Medicine ....................................... 343
  National Institute of General Medical Sciences ................. 343
  National Institute of Standards and Technology .................. 344
Role of Academic Institutions in the USA ......................... 345
  Clinical Proteomics Program ......................................... 345
  Coriell Personalized Medicine Collaborative™ ................... 345
  Delaware Valley Personalized Medicine Project ................. 346
  Evaluation of Genetic Tests and Genomic Applications ........ 347
  Genomic-Based Prospective Medicine Project .................... 347
  Personalized oncology at Massachusetts General Hospital .... 348
  Pharmacogenetics Research Network and Knowledge Base .... 349
  Quebec Center of Excellence in Personalized Medicine ......... 349
Southeast Nebraska Cancer Center’s Personalized
  Medicine Network ....................................................... 350
Wisconsin Genomics Initiative ........................................... 350
Role of Healthcare Organizations and Hospitals ................ 350
  Signature Genetics ....................................................... 351
  The Mayo Clinic Genetic Database .................................... 351
Research Center for Personalized Medicine at
  Mt. Sinai Medical Center ............................................... 352
Role of the Medical Profession ........................................... 352
  Education of the Physicians .......................................... 352
  Off-Label Prescribing and Personalized Medicine ............... 353
  Medical Education ....................................................... 353
Education of the Public .................................................... 354
  Role of the Internet in Development of Personalized Medicine 354
  Public Attitude Towards Personalized Medicine ................. 355
Global Scope of Personalized Medicine ............................. 356
  Personalized Medicine in the Developed Countries ............. 356
  US HHSs Supports Personalized Medicine ......................... 356
  Personalized Medicine in the USA .................................... 357
  Personalized Medicine in the EU ..................................... 357
  UK National Health Service and Medical Genetics ............... 358
  Personalized Medicine in the Developing Countries ............ 358
Advantages and Limitations of Personalized Medicine .......... 359
Summary .............................................................. 361
Contents

16 Ethical and Regulatory Aspects of Personalized Medicine ........................................ 363
   Introduction to Ethical Issues.................................................................................. 363
   Ethical Issues of Pharmacogenetics ...................................................................... 363
   Ethical Aspects of Genetic Information .................................................................. 364
   Ethical Issues of Whole Genome Analysis ............................................................ 364
   Ethical Aspects of Direct-to-Consumer (DTC) Genetic Services ......................... 365
   Privacy Issues in Personalized Medicine ............................................................... 367
   Genetic Information Nondiscrimination Act in the USA ......................................... 367
   Genotype-Specific Clinical Trials ........................................................................ 368
   Social Issues in Personalized Medicine ................................................................ 368
   Race and Personalized Medicine ......................................................................... 369
   Regulatory Aspects ............................................................................................... 371
   CLSI Guideline for the Use of RNA Controls in
   Gene Expression Assays ......................................................................................... 372
   Microarray Quality Control Project ....................................................................... 372
   Regulatory Aspects of Pharmacogenetics ............................................................... 373
   Regulation of DTC Genetic Testing ........................................................................ 374
   FDA and Pharmacogenomics ................................................................................ 375
      FDA Guidance for Pharmacogenomic Data Submissions .................................... 375
   Joint Guidelines of the FDA and EU Regulators
      for Pharmacogenomics ....................................................................................... 376
      Pharmacogenomic Information in Drug Labels .................................................. 376
   FDA guidelines for Pharmacogenomics-Based Dosing .......................................... 377
   FDA and Validation of Biomarkers ........................................................................ 377
   FDA and Predictive Medicine ............................................................................... 378
   FDA Regulation of Multivariate Index Assays ....................................................... 379
      Evaluation of Companion Diagnostics/Therapeutic for Cancer ......................... 381
   Summary ................................................................................................................ 381

17 Economics of Personalized Medicine ................................................................... 383
   Introduction ............................................................................................................ 383
   Perceived Financial Concerns ............................................................................... 383
   Personalized Medicine and Orphan Drug Syndrome ............................................. 384
   Commercial Aspects of Pharmacogenomics ............................................................ 384
      Cost of DNA Testing .......................................................................................... 384
      Cost of Sequencing the Human Genome ............................................................ 384
      Cost of Genotyping ........................................................................................... 387
      Cost of Pharmacogenomics-Based Clinical Trials ............................................. 388
   Cost of Personalized Healthcare .......................................................................... 389
   Cost of Genetic Testing ......................................................................................... 389
   Economics of CYP Genotyping-Based Pharmacotherapy ...................................... 390
   Cost of Personalized Medicines ............................................................................ 390
      Lowering the Cost of Healthcare in the USA ...................................................... 391
      Cost Effectiveness of HIV Genotyping .............................................................. 391
      Lowering the High Costs of Cancer Chemotherapy .......................................... 391
Reducing the Cost Incurred by Adverse Drug Reactions .......... 392
Overall Impact of Personalized Medicine on Healthcare ......... 392
Summary .................................................................................. 392

18 Future of Personalized Medicine ........................................ 395
Introduction ........................................................................... 395
Ongoing Genomic Projects ...................................................... 396
Understanding the Genetic Basis of Diseases ....................... 396
Personal Genome Project ......................................................... 396
Genome-Wide Association Studies ....................................... 397
The 1000 Genomes Project .................................................... 398
Genomics of Aging in a Genetically Homogeneous Population .. 399
Translational Science and Personalized Medicine ................. 399
Translation of Genomic Research into Genetic Testing
for Healthcare ................................................................. 399
Long-Term Behavioral Effects of Personal Genetic Testing ...... 400
Drivers for the Development of Personalized Medicine .......... 401
Evolution of Medicine as a Driver for Personalized
Therapy Markets ................................................................ 402
Personalized Predictive Medicine .......................................... 402
Opportunities and Challenges ............................................... 403
Prospects and Limitations of Genetic Testing ....................... 403
Challenges in Delivery of Personalized Medicine ................. 404
Pharmacotyping .................................................................. 405
Concluding Remarks about the Future of Personalized Medicine.. 405
Summary ................................................................................ 406

References ............................................................................. 407

Index ....................................................................................... 421
Textbook of Personalized Medicine
Jain, K.K.
2009, XXVI, 430 p., Hardcover
ISBN: 978-1-4419-0768-4